AMSSY - ams and Precision Biomonitoring collaborate to develop rapid antigen COVID-19 test solution

ams ([[AMSSY]] -3.7%) announces partnership with Canada's Precision Biomonitoring to share technologies for the development of a rapid antigen testing device for the Covid-19 (SARS-CoV-2) virus.The partnership will see ams' spectral sensor technology paired with Precision Biomonitoring's lateral flow and digital capabilities, to provide antigen test solution focused on detecting the virus at earlier stages of infection, before even symptoms would have appeared, in around 15 minutes at the point-of-care.ams says its spectral sensor solution allows fluorescence-based read out of antigen detection designed to improve speed and reliability of rapid, point-of-care diagnostics."Our initial results for this solution indicate that even asymptomatic patients who carry the virus could be more readily identified......This is aided by the fact that, once approved, the testing solution can be produced inexpensively and without complex limitations at high scale," says Jennifer Zhao, EVP, division Advanced Optical Sensors, ams.Now Read: Who's next in line to receive a coronavirus vaccine? (Dec. 21)

For further details see:

ams and Precision Biomonitoring collaborate to develop rapid antigen COVID-19 test solution